Gilead Sciences Acquires Tubulis for $5 Billion
Analysis based on 9 articles · First reported Apr 07, 2026 · Last updated Apr 10, 2026
The acquisition of Tubulis by Gilead Sciences is expected to positively impact the biotechnology and pharmaceutical markets, particularly in oncology, by accelerating the development of next-generation antibody-drug conjugates. This deal reinforces Gilead Sciences' strategic focus on cancer therapies and could lead to new treatment options for patients.
Gilead Sciences has entered into a definitive agreement to acquire Tubulis GmbH, a Germany-based clinical-stage biotechnology company, for an upfront cash consideration of $3.15 billion and up to $1.85 billion in contingent milestone payments, totaling up to $5 billion. This acquisition aims to significantly expand Gilead Sciences' oncology pipeline, specifically in the area of antibody-drug conjugates (ADCs). Tubulis' lead asset, TUB-040, is in Phase 1b/2 development for platinum-resistant ovarian cancer and non-small cell lung cancer, and TUB-030 is also included in the deal. Following the transaction, expected to close in Q2 2026, Tubulis will operate as a dedicated ADC research organization within Gilead Sciences, with its Munich site becoming a hub for ADC innovation. This move follows a two-year collaboration between the two companies and is part of Gilead Sciences' broader strategy to diversify its portfolio and address unmet needs in cancer treatment.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard